Federal News
Senate Ends GSK Inhaler Monopoly
March 16, 2026
Senator Maggie Hassan's investigation has compelled GlaxoSmithKline (GSK) to relinquish its monopoly on the asthma inhaler Flovent, enabling the entry of a lower-cost generic alternative into the U.S. market. This action addresses prior pricing strategies that limited access to affordable asthma treatment for nearly 5 million children nationwide. The Food and Drug Administration (FDA) is positioned to facilitate the approval and market introduction of generic inhalers, potentially reshaping pharmaceutical procurement dynamics for pediatric asthma care.
- Why this matters: Federal procurement and healthcare agencies may see increased availability of cost-effective asthma inhalers, impacting contract negotiations and formulary decisions.
- Procurement professionals should anticipate shifts in pharmaceutical supply chains and pricing structures for respiratory treatments.
- Contractors and vendors specializing in generic pharmaceuticals could find new market opportunities as barriers to entry diminish.
- This development underscores the role of legislative oversight in influencing pharmaceutical market competition and pricing policies.
Now that the company has given up its monopoly and finally allowed a lower-cost generic to enter the market, fewer families around the country will have to live in constant fear that their child may die from an asthma attack because GSK has priced them out of life-saving medication.
— Senator Maggie Hassan
Agencies
U.S. Senate Finance Subcommittee on Health Care, U.S. Senate, Food and Drug Administration
Vendors
GlaxoSmithKline